Outcome of childhood ALK‐positive anaplastic large cell lymphoma relapses: Real‐life experience of the French Society of Pediatric Oncology (SFCE) cohort of 75 French children
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Victor Pereira und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, Besançon University Hospital, Besançon, France. Hauptthemen laut MEDLINE: Lymphoma, Large-Cell, Anaplastic, Anaplastic Lymphoma Kinase, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objective
To describe treatments and outcomes of French children treated for relapsed/refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma (ALK+ ALCL).
Methods
We conducted the analysis of a series of 75 French children treated for a first relapsed/refractory ALK+ ALCL between 1999 and 2017.
Results
The median time to first relapse was 8.1 months from initial diagnosis (2.9 after end of treatment), with 12 relapses during frontline treatment or within 1 month of the end of treatment. Treatment of the first relapse varied according to the period of time and risk factors: 48 received multiagent chemotherapy, including 21 and 19 consolidated with allogeneic stem cell transplantation (SCT) and autologous‐SCT, respectively. Twenty‐one patients received weekly vinblastine, and six received ALK inhibitors (ALKi). Overall, 64/75 patients reached a second complete remission (CR2). Eight out of 11 patients who did not reach CR2 died and the other three were rescued with ALKi, vinblastine, and nivolumab. With a median follow‐up of 8.2 years, 60 patients are alive, 43 in CR2, 15 in CR3, two in CR4; and 15 patients died, six from toxicity and nine from disease progression. The 5‐year event‐free survival and overall survival after first relapse were 51.7% (95% confidence interval [CI]: 39.6%–62.6%) and 80.7% (95% CI: 69.6%–88.1%), respectively. Time to relapse greater than 12 months from initial diagnosis was proven to be a prognostic factor in relapsed/refractory ALK+ ALCL.
Conclusion
In relapsed ALK+ ALCL, high survival rate can be reached with various therapeutic strategies. The main challenge remains to prevent subsequent relapses, and to lower long‐term morbidity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Hematology and Oncology, Besançon University Hospital, Besançon, France.
- Department of Pediatric and adolescents Oncology, Gustave Roussy cancer Institute, Paris Saclay University, Villejuif, France.
- Department of Methodology and Biostatistics, Oscar Lambret Center, Lille, France.
- Department of Pediatric Oncology and Hematology, Bordeaux University Hospital, Bordeaux, France.
- Department of Pediatric Oncology and Hematology, University Children's Hospital of Nancy, Nancy, France.
- Department of Pediatric Hematology and Immunology, Robert Debré Academic Hospital, GHU AP-HP Nord Université Paris Cité, Paris, France.
ORCID-Profile: Victor Pereira, Nathalie Aladjidi, Bénédicte Bruno, Arnauld Verschuur, Stéphane Ducassou, Laurence Brugieres, Charlotte Rigaud
Zitieren
APA
Pereira, V., Barthoulot, M., Aladjidi, N., Contet, A., Dalle, J. H., Dourthe, M. É., Garnier, N., Bruno, B., Leruste, A., Pellier, I., Simonin, M., Paillard, C., Verschuur, A., Ducassou, S., Lamant, L., Brugieres, L., Deley, M. L., & Rigaud, C. (2025). Outcome of childhood ALK‐positive anaplastic large cell lymphoma relapses: Real‐life experience of the French Society of Pediatric Oncology (SFCE) cohort of 75 French children. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31397
Vancouver
Pereira V, Barthoulot M, Aladjidi N, Contet A, Dalle JH, Dourthe MÉ, et al. Outcome of childhood ALK‐positive anaplastic large cell lymphoma relapses: Real‐life experience of the French Society of Pediatric Oncology (SFCE) cohort of 75 French children. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31397
BibTeX
@article{Pereira2025,
author = {Pereira, Victor and Barthoulot, Maël and Aladjidi, Nathalie and Contet, Audrey and Dalle, Jean-Hugues and Dourthe, Marie Émilie and Garnier, Nathalie and Bruno, Bénédicte and Leruste, Amaury and Pellier, Isabelle and Simonin, Matthieu and Paillard, Catherine and Verschuur, Arnauld and Ducassou, Stéphane and Lamant, Laurence and Brugieres, Laurence and Deley, Marie-Cécile Le and Rigaud, Charlotte},
title = {Outcome of childhood ALK‐positive anaplastic large cell lymphoma relapses: Real‐life experience of the French Society of Pediatric Oncology (SFCE) cohort of 75 French children},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31397}
}
EUVIMED